Type I IFN signaling during lung development in Down Syndrome-Multiome sequencing of human fetal and pediatric trisomy 21 lungs
Type I IFN signaling during lung development in Down Syndrome-Multiome sequencing of human fetal and pediatric trisomy 21 lungs
批准号:
10670654
负责人:
Soula Athanasia Danopoulos
金额:
$35.28万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-17 至 2024-06-30
关键词:
ATAC-seqAdultAffectAgeAgingBirthBronchopulmonary DysplasiaCell CountCellsChildhoodChromosome 21Chromosome abnormalityCodeComplexComplicationDNA MethylationDataData SetDefectDeglutition DisordersDevelopmentDown SyndromeEpigenetic ProcessEtiologyEventFetal DevelopmentFetal LungFibroblastsFoundationsGene ExpressionGene Expression AlterationGenesGenetic TranscriptionGrowthHeartHeart DiseasesHeterogeneityHumanIncidenceIndividualInterferonsLive BirthLong-Term EffectsLungLung diseasesMechanical ventilationMetabolismMethodologyModificationMolecularMolecular AbnormalityMonozygotic twinsMorbidity - disease rateMorphologyMuscle TonusNewborn InfantNuclearNuclear RNAOrganPPAR gammaPathway interactionsPhenotypePlayPregnancyPublishingPulmonary HypertensionPulmonary PathologyReportingRoleSamplingSeveritiesSignal TransductionSkinStainsStructureSyndromeTestingThird Pregnancy TrimesterTissuesUntranslated RNAUp-RegulationVentricular Septal DefectsWorkairway musclebody systemcell typechromatin remodelingdaughter cellepigenetic profilingepigenetic regulationexperimental studyfetalgene regulatory networkgenome-wideimprovedin uteroinnovationlung developmentmortalitynovelnovel therapeuticsparent grantparent projectpostnatalprenatalpreservationresponsesexsingle-cell RNA sequencingsurfactanttranscriptome sequencingtranslational potential
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Summary/Abstract
Trisomy 21 (T21) is the most common human chromosomal anomaly, affecting 1 in 700 live births,
resulting in Down Syndrome (DS). Although DS can affect many organ systems, lung and heart disease are the
leading causes of morbidity and mortality. Several congenital lung anomalies are reported in individuals with DS
including airway branching defects, with a 25% decrease in the number of branches and reduced upper airway
muscle tone with dysphagia and/or bronchomalacia. These complications remain constant into adulthood, as
opposed to becoming exacerbated, and are hence likely due to developmental insufficiency.
While abnormal pulmonary structure and function in pediatric and adult individuals with DS has been
described, there is limited data defining the ontogeny of these abnormalities. We postulated that developmental
differences could initiate prenatally in T21 lungs and have now demonstrated pulmonary anomalies arise in
approximately 70% of T21 cases starting as early as 16 weeks gestation, as determined from experiments
proposed in the parent grant. Our single cell RNAseq data and immunofluorescent stainings have demonstrated
upregulation of the surfactant metabolism pathway and increased cell number of differentiated proximal airway
markers (SCGB1A1 and FOXJ1) respectively. Altogether these findings strongly support one of the hypotheses
proposed in the parent grant, where we postulate precocious development/differentiation in the T21 lungs as
compared to their age and sex matched controls. These observations are fitting being that DS is generally
described as a progeroid syndrome. It has been demonstrated that this accelerated aging may be associated to
genome wide perturbation due to dysregulated epigenetic regulation; however, no studies have investigated the
epigenetic landscape of the developing T21 lung. Thus, we hypothesize cellular and molecular abnormalities in
T21 lungs initiate in utero, resulting in precocious development associated with altered epigenetic regulation.
Recent advances in single cell epigenetic profiling methodology allow us to simultaneously test this hypothesis
in the same tissues we are collecting and analyzing for the parent project. We will use multiome sequencing
(single nuclear RNAseq/ATACseq) to determine the cellular and molecular abnormalities initiated during the late
pseudoglandular/early canalicular stages of fetal development in T21 lungs. Being that epigenetic modifications
are preserved in daughter cells, we will also determine alterations in gene regulatory networks at the single cell
level between prenatal and postnatal T21 lungs vs non-T21 lungs, to further define the ontogeny of pulmonary
anomalies observed in DS.
These studies have the promise to improve our understanding of the key molecular and cellular
differences, and the mechanisms controlling defects in T21 developing lungs. The innovative aspects of this
work are likely to have great overall impact in stimulating additional activity leading to progress on understanding
lung anomalies in DS and facilitate the translational potential for therapies.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
A Trisomy 21 Lung Cell Atlas.
21 三体肺细胞图谱。
DOI:
10.1101/2023.03.30.534839
发表时间:
2023
期刊:
bioRxiv : the preprint server for biology
影响因子:
--
作者:
[Bhattacharya,Soumyaroop, Cherry,Caroline, Deutsch,Gail, BirthDefectsResearchLaboratory(BDRL), Glass,IanA, Mariani,ThomasJ, Alam,DeniseAl, Danopoulos,Soula]
通讯作者:
Danopoulos,Soula
DOI:
10.3390/ijms23095265
发表时间:
2022-05-09
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[]
通讯作者:
Preferential FGF18/FGFR activity in pseudoglandular versus canalicular stage human lung fibroblasts.
DOI:
10.3389/fcell.2023.1220002
发表时间:
2023
期刊:
Frontiers in cell and developmental biology
影响因子:
5.5
作者:
[]
通讯作者:
DOI:
10.1183/13993003.02248-2020
发表时间:
2022-03
期刊:
The European respiratory journal
影响因子:
--
作者:
[Hirani D, Alvira CM, Danopoulos S, Milla C, Donato M, Tian L, Mohr J, Dinger K, Vohlen C, Selle J, V Koningsbruggen-Rietschel S, Barbarino V, Pallasch C, Rose-John S, Odenthal M, Pryhuber GS, Mansouri S, Savai R, Seeger W, Khatri P, Al Alam D, Dötsch J, Alejandre Alcazar MA]
通讯作者:
Alejandre Alcazar MA
DOI:
10.1016/j.celrep.2022.110608
发表时间:
2022-04-05
期刊:
CELL REPORTS
影响因子:
8.8
作者:
[Gao, Feng, Li, Changgong, Danopoulos, Soula, Al Alam, Denise, Peinado, Neil, Webster, Sha, Borok, Zea, Kohbodi, GoleNaz Adeli, Bellusci, Saverio, Minoo, Parviz]
通讯作者:
Minoo, Parviz
Type I IFN signaling during lung development in Down Syndrome
-
批准号:10297761
-
项目类别:
-
资助金额:$180.6万
-
财政年份:2021
-
负责人:Soula Athanasia Danopoulos
-
依托单位:
海外基金